ALSO NOTED: TransPharma raises $18M; Biogen Idec, Elan re-release Tysabri; and much more...

> TransPharma Medical, which is developing a new drug delivery technology, has raised $18 million in financing. Report

> Biogen Idec and Elan have re-released Tysabri for MS in the United States. Report

> Researchers are exploring the effectiveness of a combination of cancer-drug mitoxantrone and copaxone to treat aggressive MS. Release

> Biovail and Athpharma have terminated a development pact for four cardiovascular drugs. Report

> Barr Pharmaceuticals says it is confident that it can meet any requirements the FTC may have as a condition for buying Pliva. Report

> Nektar Therapeutics announced that it received $17.6 million from Affymax for a previously undisclosed licensing deal. Report

And Finally… Scientists at the Max Planck Institute for Evolutionary Anthropology plan to crack the genetic code of Neanderthals in order to better understand why they became extinct while modern man thrived. Article (WSJ sub. req.)